TY - JOUR
T1 - Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm
AU - Kaneko, Hidehiro
AU - Anzai, Toshihisa
AU - Takahashi, Toshiyuki
AU - Kohno, Takashi
AU - Shimoda, Masayuki
AU - Sasaki, Aya
AU - Shimizu, Hideyuki
AU - Nagai, Toshiyuki
AU - Maekawa, Yuichiro
AU - Yoshimura, Koichi
AU - Aoki, Hiroki
AU - Yoshikawa, Tsutomu
AU - Okada, Yasunori
AU - Yozu, Ryohei
AU - Ogawa, Satoshi
AU - Fukuda, Keiichi
N1 - Funding Information:
This work was supported by the Global Center of Excellence (G-COE) Program at Keio University (H.K.), a Medical School Faculty and Alumni Grant from Keio University Medical Science Fund (T.A.), and the grant from the Ministry of Health, Labor and Welfare (Research Group of Intractable Vasculitis) Japan (Y.O.).
PY - 2011/7/15
Y1 - 2011/7/15
N2 - AimsIncreased angiogenesis, chronic inflammation, and extracellular matrix degradation are the major pathological features of abdominal aortic aneurysm (AAA). We sought to elucidate the role of vascular endothelial growth factor (VEGF)-A, a potent angiogenic and proinflammatory factor, in the development of AAA.Methods and resultsHuman AAA samples showed increased VEGF-A expression, neovascularization, and macrophage infiltration compared with normal aortic walls. AAA was induced in mice by periaortic application of CaCl2. AAA mice were treated with soluble VEGF-A receptor (sFlt)-1 or phosphate-buffered saline and sacrificed 6 weeks after the operation. Treatment with sFlt-1 resulted in reduced aneurysm size, restored wavy structure of the elastic lamellae, reduced Mac-2+ monocytes/macrophages, CD3+ T-lymphocytes, and CD31+ vessels, and attenuated matrix metalloproteinase (MMP)-2 and 9 activity in periaortic tissue of AAA. Increased aortic mRNA expression of monocyte chemotactic protein-1, tumour necrosis factor-α, and intercellular adhesion molecule-1 in AAA was attenuated by sFlt-1 treatment.ConclusionVEGF-A was overexpressed in the aortic wall of human and experimental AAA. Treatment with sFlt-1 inhibited AAA development in mice, in association with reduced neoangiogenesis, infiltration of inflammatory cells, MMP activity, and extracellular matrix degradation. These findings suggest a crucial role of VEGF-A in the development of AAA.
AB - AimsIncreased angiogenesis, chronic inflammation, and extracellular matrix degradation are the major pathological features of abdominal aortic aneurysm (AAA). We sought to elucidate the role of vascular endothelial growth factor (VEGF)-A, a potent angiogenic and proinflammatory factor, in the development of AAA.Methods and resultsHuman AAA samples showed increased VEGF-A expression, neovascularization, and macrophage infiltration compared with normal aortic walls. AAA was induced in mice by periaortic application of CaCl2. AAA mice were treated with soluble VEGF-A receptor (sFlt)-1 or phosphate-buffered saline and sacrificed 6 weeks after the operation. Treatment with sFlt-1 resulted in reduced aneurysm size, restored wavy structure of the elastic lamellae, reduced Mac-2+ monocytes/macrophages, CD3+ T-lymphocytes, and CD31+ vessels, and attenuated matrix metalloproteinase (MMP)-2 and 9 activity in periaortic tissue of AAA. Increased aortic mRNA expression of monocyte chemotactic protein-1, tumour necrosis factor-α, and intercellular adhesion molecule-1 in AAA was attenuated by sFlt-1 treatment.ConclusionVEGF-A was overexpressed in the aortic wall of human and experimental AAA. Treatment with sFlt-1 inhibited AAA development in mice, in association with reduced neoangiogenesis, infiltration of inflammatory cells, MMP activity, and extracellular matrix degradation. These findings suggest a crucial role of VEGF-A in the development of AAA.
KW - Angio-/arteriogenesis
KW - Atherosclerosis
KW - Growth factors
KW - Inflammation
KW - Macrophages
UR - http://www.scopus.com/inward/record.url?scp=79960005595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960005595&partnerID=8YFLogxK
U2 - 10.1093/cvr/cvr080
DO - 10.1093/cvr/cvr080
M3 - Article
C2 - 21436157
AN - SCOPUS:79960005595
SN - 0008-6363
VL - 91
SP - 358
EP - 367
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 2
ER -